Yes, you've got it. That's the point I'm trying to make.
009 A1C reductions weren't good enough for approval and the first CRL was issued.
117 data was used as a response to the first CRL and A1C reductions shown in 117 were good enough for approval.
But we just received word that A1C reductions from the most recent trial (171) were similar to the reductions seen in 009.
If the above is true, this puts the company in an uncomfortable position.
